Gilead did not seek US exclusivity on PrEP with Truvada
Drugmaker could be liable for billions in royalties to US government (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 18, 2019 Category: Pharmaceuticals Source Type: news
Would You Want a Computer to Judge Your Risk of H.I.V. Infection?
A new software algorithm decides which patients are most likely to become infected with the virus. But this is not like other risk calculators, some experts say. (Source: NYT Health)
Source: NYT Health - July 30, 2019 Category: Consumer Health News Authors: Gina Kolata Tags: Tests (Medical) Truvada (Drug) Acquired Immune Deficiency Syndrome Electronic Health Records Computers and the Internet Homosexuality and Bisexuality Sexually Transmitted Diseases Harvard University Kaiser Permanente United States Source Type: news
Most High-Risk Men Don ’t Take PrEP to Prevent H.I.V.
In a survey, only about one in three American men who were at high risk for H.I.V. infection took Truvada to prevent transmission. (Source: NYT Health)
Source: NYT Health - July 25, 2019 Category: Consumer Health News Authors: Toby Bilanow Tags: Truvada (Drug) Acquired Immune Deficiency Syndrome Sexually Transmitted Diseases Blacks Condoms Hispanic-Americans Source Type: news
Someday, an Arm Implant May Prevent H.I.V. Infection for a Year
In preliminary tests, a matchstick-size rod containing a new drug offered promise as a shield against the virus. But a large clinical trial must still be done. (Source: NYT Health)
Source: NYT Health - July 23, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Inventions and Patents Implants Merck & Company Inc National Institute for Allergy and Infectious Disease (NIAID) Fauci, Anthony S Africa Source Type: news
PrEP use high but wanes after three months among young African women
(NIH/National Institute of Allergy and Infectious Diseases) In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among young African women and adolescent girls, 95% initiated PrEP, and most used PrEP for the first three months. However, PrEP use fell in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored strategies may be needed to engage young African women in consistent PrEP use. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 23, 2019 Category: Infectious Diseases Source Type: news
Lower than expected risk of bone density decline with Truvada PrEP
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use -- very high adherence -- had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2019 Category: International Medicine & Public Health Source Type: news
How Australia Could Almost Eradicate H.I.V. Transmissions
The most recent advance in Australia ’s decades-long fight against the virus is the rapid adoption of a preventive drug regimen known as PrEP. (Source: NYT Health)
Source: NYT Health - July 10, 2019 Category: Consumer Health News Authors: Livia Albeck-Ripka Tags: Truvada (Drug) Acquired Immune Deficiency Syndrome Health Insurance and Managed Care Homosexuality and Bisexuality Australia United States Source Type: news
Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2019 Category: Drugs & Pharmacology Source Type: news
FDA In Brief: FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV
Because patients and doctors understand the risks of using Truvada for PrEP, and educational materials are available from CDC, FDA eliminated the REMS for Truvada and its generics. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 2, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
UCLA Health to launch fellowship focused on LGBTQ care
To help ensure that future primary care doctors are able to address the physical and mental health care needs of people who are LGBTQ, UCLA Health has created an immersive, one-year fellowship focused on LGBTQ-centered care.TheUCLA LGBTQ Fellowship, which starts on July 1, was conceived about a year ago by faculty in the internal medicine department at theDavid Geffen School of Medicine at UCLA to address LGBTQ-specific topics, which often are not adequately addressed in medical school and residency training.The training will help doctors provide the best counsel for disease prevention and screening, sexual and behavioral ...
Source: UCLA Newsroom: Health Sciences - June 21, 2019 Category: Universities & Medical Training Source Type: news
Expert Panel Backs PrEP for People at High HIV Risk
Best known as the two-drug combo pill Truvada, PrEP prevents HIV from establishing a permanent infection in people exposed through sex or injection drug use, the CDC says. (Source: WebMD Health)
Source: WebMD Health - June 11, 2019 Category: Consumer Health News Source Type: news
For the First Time, an Expert Panel Is Recommending a Drug to Prevent High-Risk Groups From Getting HIV
Over the past few decades, doctors and researchers have made admirable progress in controlling the spread of HIV, mainly by using anti-HIV drugs in powerful combinations that can make it harder for the virus to infect cells and pump out more copies of itself. But as any infectious-disease expert knows, preventing new infections is equally as important as treating existing cases to contain an epidemic. And in the U.S. each year, nearly 40,000 people are still newly diagnosed with HIV.
With its latest recommendation, published in JAMA, the U.S. Preventive Services Task Force (USPSTF) issued its strongest strategy yet for pre...
Source: TIME: Health - June 11, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV hiv prevention Infectious Disease Source Type: news
U.S. Expert Panel Supports HIV-Prevention Pill Truvada, for People at High Risk
TUESDAY, June 11, 2019 -- A daily pill that can block transmission of HIV should be prescribed to people at high risk of infection with the AIDS-causing virus, according to a highly influential panel of experts.
The treatment -- called pre-exposure... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2019 Category: General Medicine Source Type: news
Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment
A single-tablet regimen of bictegravir, emtricitabine and tenofovir alafenamide is noninferior to regimens of dolutegravir coformulated with emtricitabine and tenofovir alafenamide or with abacavir and lamivudine for the initial treatment of HIV-1 infection, according to results from two randomized phase 3 trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 7, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Health activists fighting to lower cost of a revolutionary HIV drug
The organization PrEP4All is facing off with a major pharmaceutical company over the growing price of Truvada, a revolutionary HIV drug. A 30-day supply of Truvada costs around $1,700. No cheaper version of the same drug is available in the United States. Health advocate Emily Sanderson joins CBSN to disucss. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 5, 2019 Category: Consumer Health News Source Type: news
